Linked Life Data

6591741

Source:http://linkedlifedata.com/resource/pubmed/id/6591741

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1984-9-27
pubmed:abstractText
A new, non-ionic low osmolar contrast medium, iohexol 240 mg I/ml, has been tested in a randomized double blind parallel investigation versus meglumine-Ca metrizoate 200 mg I/ml. The study was performed to evaluate the suitability of the contrast medium in phlebography. No post-phlebographic complications were seen in the 24 patients examined with iohexol 240 mg I/ml or in 8 patients examined with iohexol 300 mg I/ml. In the 19 patients examined with metrizoate 200 mg I/ml, 7 had a post-phlebographic thrombotic complication (37%). The radiographic image quality was not significantly different between the two contrast media, neither were the immediate side effects during contrast injections. It has thus been shown that iohexol is a suitable contrast medium in phlebography of the lower limb and that it is preferable to conventional contrast media.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0365-5954
pubmed:author
pubmed:issnType
Print
pubmed:volume
366
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
58-64
pubmed:dateRevised
2008-4-9
pubmed:meshHeading
pubmed:year
1983
pubmed:articleTitle
Double blind comparison between iohexol and metrizoate in phlebography of the lower limb.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't